NYSE$MCK

McKesson Corp · Q4 2026 earnings

Q4 2026 earnings · · After market close · Investor relations

Briefing

McKesson reported fiscal Q4 2026 revenues of $96.3B (+6% YoY) with diluted EPS of $13.71 and fiscal 2027 adjusted EPS guidance of $43.80–$44.60.

For the fourth quarter ended March 31, 2026, McKesson reported revenues of $96.3 billion, up 6%, and net income attributable to McKesson of $1.68 billion. Diluted EPS was $13.71 versus $10.01 a year ago; adjusted diluted EPS was $11.69, up 16%. Full-year revenues were $403.4 billion (+12%) with adjusted EPS of $39.11 (+18%). Management established fiscal 2027 adjusted EPS guidance of $43.80 to $44.60 (12–14% growth) and reaffirmed long-term adjusted EPS growth of 13–16%.

  • Q4 revenue $96.3B (+6%); diluted EPS $13.71; adjusted EPS $11.69 (+16%).
  • FY26 revenue $403.4B (+12%); adjusted EPS $39.11 (+18%).
  • FY27 adjusted EPS guidance $43.80–$44.60.
  • $5.0B added to share repurchase authorization; $2.25B ASR in Q4.

Headline financials

Total Revenue

$96.3B

Previous: $90.8B+6.0%
EPS (adj)

$11.69

Previous: $11.69+0.0%
Net Income

$1.86B

Previous: $1.31B+42.0%
Operating Income

$2.15B

Previous: $1.59B+35.1%
Gross Profit

$4.04B

Previous: $3.64B+11.1%
Cash & Equivalents

$3.98B

No prior period
Total Assets

$82.3B

No prior period

Revenue & EPS history

McKesson · Revenue · Quarterly

$96.3B

Q4 2026+6%vs Q4 2025
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Revenue by segment

McKesson · $3.97B total across 2 segments · Q2 2024

  • Medical-Surgical Solutions
    $2.83B-0.3%
  • Prescription Technology Solutions
    $1.14B+12.0%

Forward guidance

McKesson established fiscal 2027 adjusted diluted EPS guidance of $43.80 to $44.60 (12–14% growth) and reaffirmed long-term adjusted EPS growth of 13–16%. GAAP EPS is not forecast.

Tailwinds

  • Oncology & Multispecialty segment revenue +35% in Q4.
  • $7.7B total repurchase authorization after $5B increase.
  • Free cash flow $3.2B in Q4; $5.4B for the year.

Headwinds

  • Medical-Surgical separation and portfolio changes add execution risk.
  • Lower branded pharmaceutical contributions in distribution.
  • Seasonality and fewer days affected sequential net income.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2026

Historical avgQ4 2026

+1.2%

Avg return

Earnings day

+0.6%

Avg return

5 days after

+1.1%

Avg return

30 days after

60%

44 / 73 earnings

Positive

+16.5%

Q3 2026

Best reaction

-21.7%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+0.2%-3.4%+2.8%
Q3 2026+16.5%+13.8%+11.8%
Q2 2026+1.5%+1.4%-4.2%
Q1 2026-5.8%-6.4%-2.3%
Q4 2025+0.4%-1.2%+3.3%
Q3 2025-1.2%+0.6%+6.1%
Q2 2025+15.7%+17.2%+14.9%
Q1 2025-10.9%-10.3%-17.9%
Q4 2024+1.9%+5.0%+9.9%
Q3 2024-2.5%-2.4%+4.1%
Q2 2024-1.7%+1.0%+2.0%
Q1 2024+7.4%+4.2%+1.8%
Q4 2023+6.2%+6.6%+5.1%
Q3 2023-3.2%-5.4%-8.7%
Q2 2023+0.1%+1.9%-2.5%
Q1 2023+0.8%+3.7%+8.6%
Q4 2022+4.5%+3.1%-1.1%
Q3 2022+4.1%+5.2%+9.7%
Q2 2022+5.3%+6.6%+3.6%
Q1 2022-3.3%-4.6%-0.1%
Q4 2021+4.5%+4.7%+3.1%
Q3 2021+1.0%+1.9%-4.1%
Q2 2021+9.2%+12.4%+17.8%
Q1 2021+4.6%+1.2%+4.1%
Q4 2020+0.8%+3.3%+8.3%
Q3 2020+5.7%+8.6%+0.8%
Q2 2020-11.0%-7.9%-3.2%
Q1 2020+4.0%+1.5%-3.0%
Q4 2019+7.1%+0.6%+3.7%
Q3 2019+1.9%+5.4%-0.4%
Q2 2019-2.6%+2.1%-0.3%
Q1 2019-7.1%-5.8%-2.8%
Q4 2018-0.7%-3.8%+1.4%
Q3 2018-5.7%-9.7%-11.2%
Q2 2018-10.4%-8.9%-4.4%
Q1 2018-2.3%-3.1%-11.3%
Q4 2017+7.7%+11.9%+12.5%
Q3 2017-6.6%-7.6%+1.7%
Q2 2017-21.7%-18.5%-9.8%
Q1 2017-1.4%-2.1%-6.9%
Q4 2016+2.7%
Q3 2016-6.4%
Q2 2016-2.0%
Q1 2016-4.1%
Q4 2015+1.7%
Q3 2015+5.7%
Q2 2015-2.1%
Q1 2015+2.2%
Q4 2014+5.3%
Q3 2014+0.7%
Q2 2014+8.3%
Q1 2014+5.4%
Q4 2013+7.3%
Q3 2013-2.3%
Q2 2013+3.4%
Q1 2013-1.0%
Q4 2012-0.7%
Q3 2012+3.0%
Q2 2012+6.3%
Q1 2012+0.7%
Q4 2011-0.2%
Q3 2011+2.3%
Q2 2011+6.0%
Q1 2011-0.7%
Q4 2008+3.8%
Q4 2010+3.8%
Q3 2010-3.1%
Q3 2009-3.1%
Q2 2010-3.2%
Q2 2009+8.9%
Q1 2009+8.9%
Q1 2010+8.9%
Q4 2009+8.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro